Product Description
A novel anti-PD-1 x IL-10M immunocytokine for cancer therapy. (Sourced from: https://www.linkedin.com/posts/faponbiotech_therapeutic-antibodies-immunocytokine-activity-7197105777872953344-Swxe)
Mechanisms of Action: PD-1 Inhibitor,IL10 Modulator
Novel Mechanism: Yes
Modality: Cytokine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fapon Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for FP-008](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|